24/7 Market News Snapshot 27 February, 2025 – Quoin Pharmaceuticals, Ltd. American Depositary Shares (NASDAQ:QNRX)

February 27, 2025

DENVER, Colo., 27 February, 2025 (247marketnews.com) – (NASDAQ:QNRX) are discussed in this article.
Quoin Pharmaceuticals Ltd. has caught attention in the financial markets, reflecting a surge in stock value with shares experiencing a notable increase of 16.31% today, trading at $0.358 after closing at $0.308 in the previous session. The impressive trading volume of approximately 140.05 million shares demonstrates heightened investor engagement, indicative of strong bullish momentum surrounding the company. Traders are advised to observe key support and resistance levels alongside volume trends to assess potential market movements.

Simultaneously, Quoin Pharmaceuticals has made significant strides in its clinical development, showcasing promising results related to its investigational therapy, QRX003, designed to address Netherton Syndrome, a severe genetic skin disorder. Recently, the first pediatric patient to receive whole-body application of QRX003 exhibited substantial improvement within just two weeks. The investigator’s assessment highlighted a notable transformation in the patient’s skin condition, accompanied by a marked reduction in itch severity, with the patient experiencing a remarkable alleviation from multiple medications that previously disrupted her quality of life.

The Investigator’s Global Assessment (IGA) score saw a rapid enhancement—from a baseline level of five to an impressive one—after 14 days of treatment. Likewise, the pruritus score improved from a debilitating seven down to a manageable one to two, signaling a significant reduction in discomfort. Dr. Michael Myers, CEO of Quoin Pharmaceuticals, expressed enthusiasm for these promising results, emphasizing QRX003’s potential to substantially improve the lives of children affected by Netherton Syndrome.

As the company prepares to extend its clinical trials to include a broader pediatric patient population, Quoin Pharmaceuticals is positioned to play a pivotal role in offering innovative solutions for rare skin diseases, underscoring its commitment to addressing critical unmet medical needs.

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.